How does metoclopramide (Reglan) treat nausea, vomiting, and gastro‑esophageal reflux disease?

Mechanism of Action of Metoclopramide

Metoclopramide works primarily as a dopamine (D2) receptor antagonist at the chemoreceptor trigger zone in the brain to control nausea and vomiting, while also enhancing gastric motility through sensitization of tissues to acetylcholine and activation of serotonin (5-HT4) receptors in the gastrointestinal tract. 1

Antiemetic Mechanism

• Metoclopramide blocks dopamine D2 receptors centrally at the medullary chemoreceptor trigger zone (CTZ), preventing dopamine-mediated stimulation of nausea and vomiting. 1, 2
• The drug also has peripheral dopamine receptor antagonist effects that contribute to its antiemetic properties. 1
• At higher doses, metoclopramide exhibits 5-HT3 receptor antagonism, which adds to its antiemetic efficacy. 3

Prokinetic Mechanism for GERD

• Metoclopramide increases lower esophageal sphincter (LES) pressure in a dose-dependent manner, with effects beginning at 5 mg and increasing through 20 mg, lasting 2-3 hours at the higher dose. 1
• The drug sensitizes gastrointestinal tissues to the action of acetylcholine without directly stimulating gastric, biliary, or pancreatic secretions. 1
• Metoclopramide activates myenteric 5-HT4 receptors, which stimulates gastric motility and accelerates gastric emptying. 3
• It increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter, and increases duodenal and jejunal peristalsis, resulting in accelerated gastric emptying and intestinal transit. 1

Clinical Application in GERD

• In patients with gastroesophageal reflux and low LESP, metoclopramide produces dose-related increases in lower esophageal sphincter pressure, which helps prevent acid reflux. 1
• The drug significantly improves gastric emptying in GERD patients with delayed gastric emptying, accelerating emptying into the normal range. 4
• The American Gastroenterological Association recommends metoclopramide as first-line therapy for gastroparesis at 10 mg three times daily before meals, which addresses both the delayed gastric emptying and associated nausea/vomiting. 5, 6

Important Distinction from Other Drug Classes

• Metoclopramide does NOT work by decreasing gastric motility (it increases it), inhibiting the proton pump (it has no effect on acid secretion), or antagonizing acetylcholine (it sensitizes tissues to acetylcholine). 1
• Unlike anticholinergic drugs, which can abolish metoclopramide's prokinetic effects, metoclopramide's action does not depend on intact vagal innervation. 1

Clinical Considerations

• The onset of action is 30-60 minutes following oral administration, with pharmacological effects persisting for 1-2 hours. 1
• Metoclopramide carries a black box warning for tardive dyskinesia with chronic use, though the risk may be lower than previously estimated. 5
• The drug is recommended for 4-12 weeks of therapy for gastroparesis and GERD, not intended for long-term use. 2
• Common adverse effects include restlessness, drowsiness, and fatigue; extrapyramidal symptoms occur rarely and typically only with high dosage or prolonged use. 2